Europe’s medicines regulator said on March 31 the EMA had not identified any risk factors such as age, sex or a previous history of blood clotting disorders, for clotting cases reported after inoculation with AstraZeneca’s Covid-19 vaccine.

Fewer Europeans trust the AstraZeneca Covid-19 vaccine after several countries reported side effects, such as blood clots, an opinion poll by YouGov showed on March 22, even though scientific studies have found it is safe and effective.

Scientists are exploring several possibilities that might explain at least 18 reports of extremely rare blood clots in the brain that occurred in individuals in the days and weeks after receiving the AstraZeneca COVID-19 vaccine.

AstraZeneca Plc said on March 14 a review of safety data of people vaccinated with the company’s Covid-19 vaccine has shown no evidence of an increased risk of blood clots.

Multiple countries across Europe and parts of Asia suspended the use of AstraZeneca’s Covid-19 vaccine over fears the medication is leading to the development of blood clots in some patients who have received the medication.

Austrian authorities suspended inoculations with a batch of AstraZeneca’s Covid-19 vaccine as a precaution while investigating the death of one person and the illness of another after the shots, a health agency said on March 7.

The painkiller aspirin will be evaluated as a possible treatment for Covid-19 in one of Britain’s biggest trials, which will assess whether it might reduce the risk of blood clots in people with the disease.

A study of the lungs of people who have died from Covid-19 found persistent and extensive lung damage in most cases and may help doctors understand what is behind a syndrome known as ‘long Covid’, in which patients suffer ongoing symptoms for months.

Anthos Therapeutics is developing next-generation anticoagulants that do not have the bleeding risks that current blood thinners have.

A federal court upheld patent claims regarding Bristol Myers Squibb and Pfizer’s Eliquis, which blocks generic rivals from carving out a share of the market for at least six years.